Our pipeline of cancer therapies in the areas of cell therapy, immuno-oncology, and targeted therapies includes investigational therapies and next-generation technologies that have the power to transform the way cancer is treated. As we look to the future, we remain focused on advancing technologies that could someday address additional hematological malignancies and solid tumors.
PROGRAM
PHASE
Trial:
PALISADES-2
2L Relapsed/refractory diffuse large B-cell lymphoma
RMAT designation
Manufacturing innovation
Program timelines pending resolution of KITE-753 clinical hold.
Trial:
PALISADES-1
3L+ Relapsed/refractory diffuse large B-cell lymphoma
RMAT designation
Manufacturing innovation
Program timelines pending resolution of KITE-753 clinical hold.
Trial:
ARC-311
Autoimmune diseases
Trial:
HERMOSA-2
Neurology
Autoimmune diseases
Trial:
HERMOSA-1
Rheumatology
Autoimmune diseases
The safety and efficacy of these investigational agents or investigational uses of marketed products have not been established. These uses have not been approved by the US Food and Drug Administration or other regulatory authorities. There is no guarantee that these therapies or uses will be commercialized.
Some of the content on this page is not intended for users outside the US.